Get notified of page updates
Federal Public Policy Initiatives
Review some of FORCE's current legislative and regulatory policy priorities that impact the hereditary cancer community.
Policy Archive
FDA Approves New Direct-to-Consumer Genetic Test for 3 BRCA Mutations

On March 6, 2018, the Food and Drug Administration (FDA) announced approval of a new direct-to-consumer genetic test for three BRCA mutations most commonly found in people with Ashkenazi Jewish (Eastern European) ancestry, often referred to as founder mutations.
With thousands of known BRCA mutations, 23andMe's "Personal Genome Service Genetic Health Risk (GHR) Report for BRCA1/BRCA2 (Selected Variants)" provides consumers with an extremely limited snapshot of potential hereditary cancer risk.
Knowledge Can Save Lives
Receive FORCE Newsletters
Stay up to date on hereditary cancer information.
Stay up to date on hereditary cancer information.